Open Accessibility Menu

Coronavirus (COVID-19) Vaccine Update Click here to learn more.

For information about COVID-19 or to view additional resources, please click here.

  • Certified ALS Center Program
    Certified ALS Center Program
  • Level 4 Epilepsy Center - national association of epilepsy centers
    National Association of Epilepsy Centers
  • Comprehensive Stroke Center
  • AANEM EDX Lab Accreditation - exemplary status
    AANEM EDX Lab Accreditation

Mission Statement

High Quality Headache Care IN Washington DC

The GW Medical Faculty Associates Headache Center was established in July 2015 to fulfill two primary objectives:

  • To provide citizens of the region with expert consultative care in the area of headache medicine
  • To raise the existing standard of care for headache through research.

Approach to Headache Management

In treating patients with headaches and migraine headaches, the GW Headache Center is dedicated to the proposition that patients who take an active role in managing their headache disorder will experience a more favorable clinical outcome than patients who abdicate responsibility for management to the health care provider (HCP). Thus the Center places a strong emphasis on patient education, and from the initial visit onward patients are provided with a variety of educational aids to assist them in understanding the origin of their headaches and how their headache burden may be most effectively reduced. While the Center’s provider is always available to serve as “navigator” and, specifically, to explain the various management options available. Treatment itself is a “two-way street”: a therapeutic alliance in which the patient is an active participant.

New Patients

Patients who come to the Center’s clinics receive a thorough evaluation by neurology providers who have been trained specifically in the field of headache medicine, and each patient is provided with a specific diagnosis and a management plan that is tailored to his/her particular needs.

Established Patients

Patients who have been evaluated at the Center and are having difficulties despite following the management plan designed for them are advised to contact the Center to request assistance. If the patient’s problem cannot be managed by email or phone, he/she will be scheduled for prompt clinic follow-up and a face-to-face evaluation.

Providers Referring to the Center

  • Physicians and other HCPs who refer a patient to the Headache Center’s clinics for evaluation will receive an electronic communication from the Center provider who personally evaluated the patient, and that communication will contain both the provider’s clinical impression and a detailed management plan.
  • Patients referred to the Center’s clinics can be managed in one of two ways: (1) a one-time consultation, wherein a detailed management plan is outlined for the referring HCP, or (2) total comprehensive and continued care for the patient’s headache disorder is assumed by the Center.
  • Referring providers should specify which option they prefer.
  • Patients referred to the Center’s clinics who are eligible for participation in an ongoing clinical research trial and choose to participate will be followed closely by the Center’s providers and research staff for the duration of the study and seen regularly at the GW Headache Research Center, in the Center’s clinics or both. Such follow-up will be conducted in parallel with any care provided by the referring HCP, and that provider will receive regular updates as to the patient’s clinical status while enrolled in the research study.
  • If a patient who was referred to the Center does poorly from the headache standpoint despite implementation of the recommended management plan, the patient’s primary care provider (or the provider who initially referred the patient) is encouraged to refer the patient back to the Center for repeat evaluation.

Co-Directors, The GW Medical Faculty Associates Headache Center:

Amanda Tinsley, M.D.

John F. Rothrock, M.D.

To print this mission statement document, click here.

Conveniently Located

Clinical Trials

  • Phase 3 ALS study (CY 5031) with reldesemtiv. (Cytokinetics)
    This is a Phase 3, double-blind, randomized, placebo-controlled trial of reldesemtiv in patients aged 18 to 80 with ALS to assess the effect of reldesemtiv versus placebo on functional outcomes in ALS
  • Food as Medicine to Improve Lifestyle for Stroke Patients (FAMILY (CAFB))
    The purpose of this study is to evaluate if groceries delivered every two weeks, along with nutrition education and nutrition counseling, will improve the health of individuals who have recently had a stroke.
  • Sleep for Stroke Management And Recovery Trial (SleepSmart)
    Investigator-initiated, phase 3 multicenter, prospective randomized open-, blinded-endpoint (PROBE) controlled trial to test whether treatment of obstructive sleep apnea (OSA) with continuous positive airway pressure is effective for secondary prevention and recovery after stroke.
  • Preventative treatment of migraine: Outcomes for patients in realy-world healthcare systems (Triumph)
    This study is a 24-month prospective, multicenter, international, 2-stage noninterventional study reflecting treatment within real-world settings of patients with migraine who are switching or initiating pharmacologic treatment for migraine prevention
  • A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab in Patients with Migraine in Routine Clinical Practice (TV48125)
    A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab in Patients with Migraine in Routine Clinical Practice
  • A 12 month prospective, randomized, interventional, global, multicenter, active-controlled study comparing sustained benefit of two treatment paradigms (erenumab qm vs oral prophylactics) in adult episodic migraine patients (AMG334A2401)
    This study uses a single-cohort, 2-treatment arm (erenumab versus oral SoC prophylactic treatment), parallel-group randomized (2:1 [erenumab (70mg or 140mg): SoC oral prophylactic]), open-label design in adult patients with episodic migraine who have previously failed 1 or 2 prophylactic migraine treatments.
  • A phase 4, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of erenumab in adults with chronic migraine and medication overuse headache (Amgen20170703)
    Study 20170703 is a phase 4, randomized, double-blind, double-dummy, parallel-group, placebo-controlled study to evaluate the safety and efficacy of erenumab against placebo in a CM population with MOH and prior history of treatment failure.
  • A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety and tolerability of atogepant for the prevention of chronic migraine (Allergan3101-303-002)
    Multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and tolerability of atogepant 30 mg twice per day (BID) and 60 mg once daily for the prevention of chronic migraine (CM).
  • A phase 2, randomized, placebo-controlled study to evaluate the safety, tolerability and efficacy of TAK-079 in patients with generalized myasthenia gravis (TAK079-1005)
    This is a phase 2, randomized, double-blind, placebo-controlled study designed to assess the safety, tolerability, and efficacy of TAK-079 in patients with generalized MG in combination with standard background therapy.
  • A phase 3, randomized, double-blind, placebo-controlled study evaluating efficacy and safety of rozanolixizumab in adult patients with generalized myasthenia gravis (UCB MG0003)
    This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, 3-arm, repeat dose study evaluating the efficacy and safety of two doses of rozanolixizumab and matching placebo in patients with generalized MG who experience moderate to severe symptoms (Myasthenia Gravis Foundation of America [MGFA II-IVa]) and are being considered for additional treatment such as IVIg or PEX
  • A phase II study to evaluate the safety and tolerability of pyridostigmine when given with ondansetron to subjets with anti-AChR postive myasthenia gravis (DAS-MG)
    This is a phase II, single center, randomized, double-blind, placebo-controlled, study in patients with a diagnosis of anti-AchR antibody positive myasthenia gravis to compare the gastrointestinal (GI) side effects of pyridostigmine alone and when given with ondansetron in patients with a known diagnosis of anti-AchR antibody positive myasthenia gravis and current (i.e., past 7 days) pyridostigmine-related GI side effects
  • A phase 3, multicenter, open-label extension study of Zilucoplan in subjects with generalized myasthenia gravis (RA Pharma 302: Raise XT)
    Study RA101495-02.302 is a multicenter, open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study. The visit schedule during the first 12 weeks of Study RA101495-02.302 (RAISE)